Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at City of Hope

Sites in Duarte, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1044
Shown on this page
12
Current sort
Recently updated
Campus scope
City of Hope, Duarte, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within City of Hope, Duarte, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 817–828 of 1,044 matching trials with a site at City of Hope, Duarte, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational Accepts healthy volunteers

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

NCT04472338
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older · Male only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Recruiting No phase listed Observational

Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer

NCT07587229
Status at this site: Recruiting
View directory record Official record
Conditions
Gastric Cancer
Interventions
Observational study (no intervention)
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Active, not recruiting Phase 1 Interventional

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

NCT04003649
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Glioblastoma, Refractory Glioblastoma
Interventions
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Not yet recruiting Phase 1 Interventional

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

NCT07583303
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Single Agent Therapy
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Active, not recruiting Not applicable Interventional Results available

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911
Site status not listed — check the official record
View directory record Official record
Conditions
DCIS, Ductal Carcinoma in Situ
Interventions
Surgery, Active Monitoring
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
40 Years to 99 Years · Female only
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
141
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Active, not recruiting Phase 1 Interventional

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

NCT04150887
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Azacitidine, Venetoclax
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
11
States / cities
Duarte, California • Louisville, Kentucky • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Active, not recruiting Phase 2 Interventional

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

NCT04801797
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Not yet recruiting Phase 2 Interventional

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07582159
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Tafasitamab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Active, not recruiting Phase 2 Interventional

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Venetoclax, Azacitidine
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Active, not recruiting Phase 1 Interventional Results available

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

NCT02192359
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade III Glioma
Interventions
Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Placebo, Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 5, 2026, 4:31 AM EST
Not yet recruiting Phase 2 Interventional

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

NCT07578025
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03, Computed Tomography, Zanzalintinib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 5, 2026, 4:31 AM EST

About this City of Hope institution page

What this page lists
ClinicalTrials.gov records that list City of Hope in Duarte, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.